Cargando…

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer

BACKGROUND: Human epidermal growth factor receptor 2(HER2) status is a crucial predictive factor for prognostic assessment and targeted therapy selection, which may be influenced by intratumor heterogeneity and molecular divergence between the primary site and different metastases. Therefore, we per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Xiuwen, Liu, Binliang, Niu, Yunyun, Dong, Xin, Zhu, Xia, Li, Chunxiao, Li, Lixi, Yi, Zongbi, Sun, Xiaoying, Chen, Hongyan, Lu, Sijia, Ma, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375665/ https://www.ncbi.nlm.nih.gov/pubmed/31927339 http://dx.doi.org/10.1016/j.breast.2019.12.010

Ejemplares similares

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study
por: Liu, Binliang, et al.
Publicado: (2018)

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
por: Yi, Zongbi, et al.
Publicado: (2020)

Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer
por: Mo, Hongnan, et al.
Publicado: (2020)

Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients
por: Liu, Binliang, et al.
Publicado: (2020)

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
por: Ma, Fei, et al.
Publicado: (2016)

The molecular tumor burden index as a response evaluation criterion in breast cancer
por: Yi, Zongbi, et al.
Publicado: (2021)

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China
por: Yi, Zongbi, et al.
Publicado: (2020)

Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells
por: Guan, Xiuwen, et al.
Publicado: (2016)

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC
por: Tang, Yu, et al.
Publicado: (2022)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Multi-omics fusion analysis models with machine learning predict survival of HER2-negative metastatic breast cancer: a multicenter prospective observational study
por: Wang, Jiani, et al.
Publicado: (2023)

Detection of HER2 amplification in circulating free DNA in patients with breast cancer
por: Page, K, et al.
Publicado: (2011)

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
por: Guan, Xiuwen, et al.
Publicado: (2016)

To Track or Not to Track: User Reactions to Concepts in Longitudinal Health Monitoring
por: Beaudin, Jennifer S, et al.
Publicado: (2006)

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
por: Takegawa, Naoki, et al.
Publicado: (2015)

Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer
por: Krishnamurthy, Savitri, et al.
Publicado: (2013)

Prognostic Value of the Serum HER2 Extracellular Domain Level in Breast Cancer: A Systematic Review and Meta-Analysis
por: Wu, Yun, et al.
Publicado: (2022)

Breast Cancer in Chinese Females Aged 25 Years and Younger
por: Li, Lixi, et al.
Publicado: (2021)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

Is HER2 amplification predictable by digital immunohistochemistry?
por: Micsik, Tamás, et al.
Publicado: (2013)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

Mutational characteristics determined using circulating tumor DNA analysis in triple‐negative breast cancer patients with distant metastasis
por: Rong, Guohua, et al.
Publicado: (2020)

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
por: Flores, L M, et al.
Publicado: (2010)

Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer
por: Kim, Yong-Seok, et al.
Publicado: (2008)

HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours
por: Brożek, Izabela, et al.
Publicado: (2006)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer
por: Chen, Zuhua, et al.
Publicado: (2019)

HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis
por: Xu, Qian-Qian, et al.
Publicado: (2016)

Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
por: Tao, Lianyuan, et al.
Publicado: (2019)

Amplification of HER2 is a marker for global genomic instability
por: Ellsworth, Rachel E, et al.
Publicado: (2008)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_nnnb3ovhm97gmn707ok5eqo5or